Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II first-in-human study of ISM6331 in advanced or metastatic mesothelioma or other advanced solid tumors
CTR20244045Phase 2Active
- Sponsor
- Insilico Medicine
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ISM6331 in mesothelioma and Nonhematologic neoplasms, sponsored by Insilico Medicine. Primary endpoints: Dose-limiting toxicity incidence, Incidence and severity of adverse events and 1 more. Started Dec 2024; status: active.
02
Drugs
ISM6331
03
Conditions
mesotheliomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244045.